Journal Article

DKFZ-2023-00917

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.

Reissig, T. M.DKFZ* ; Tzianopoulos, I.DKFZ* ; Liffers, S.-T.DKFZ* ; Rosery, V. K.DKFZ* ; Guyot, M. ; Ting, S. ; Wiesweg, M.DKFZ* ; Kasper, S.DKFZ* ; Meister, P. ; Herold, T. ; Schmidt, H. H. ; Schumacher, B. ; Albers, D. ; Markus, P. ; Treckmann, J. ; Schuler, M.DKFZ* ; Schildhaus, H.-U.DKFZ* ; Siveke, J. T.DKFZ*

2023
BMJ London

This record in other databases:

Please use a persistent id in citations: doi:10.1016/j.esmoop.2023.101539

Abstract: Pancreatic cancer has a dismal prognosis. One reason is resistance to cytotoxic drugs. Molecularly matched therapies might overcome this resistance but the best approach to identify those patients who may benefit is unknown. Therefore, we sought to evaluate a molecularly guided treatment approach.We retrospectively analyzed the clinical outcome and mutational status of patients with pancreatic cancer who received molecular profiling at the West German Cancer Center Essen from 2016 to 2021. We carried out a 47-gene DNA next-generation sequencing (NGS) panel. Furthermore, we assessed microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status and, sequentially and only in case of KRAS wild-type, gene fusions via RNA-based NGS. Patient data and treatment were retrieved from the electronic medical records.Of 190 included patients, 171 had pancreatic ductal adenocarcinoma (90%). One hundred and three patients had stage IV pancreatic cancer at diagnosis (54%). MMR analysis in 94 patients (94/190, 49.5%) identified 3 patients with dMMR (3/94, 3.2%). Notably, we identified 32 patients with KRAS wild-type status (16.8%). To identify driver alterations in these patients, we conducted an RNA-based fusion assay on 13 assessable samples and identified 5 potentially actionable fusions (5/13, 38.5%). Overall, we identified 34 patients with potentially actionable alterations (34/190, 17.9%). Of these 34 patients, 10 patients (10/34, 29.4%) finally received at least one molecularly targeted treatment and 4 patients had an exceptional response (>9 months on treatment).Here, we show that a small-sized gene panel can suffice to identify relevant therapeutic options for pancreatic cancer patients. Informally comparing with previous large-scale studies, this approach yields a similar detection rate of actionable targets. We propose molecular sequencing of pancreatic cancer as standard of care to identify KRAS wild-type and rare molecular subsets for targeted treatment strategies.

Keyword(s): Archer ; KRAS wild-type ; NGS ; targeted sequencing ; targeted therapy

---

Contributing Institute(s):

1. DKTK ED ES zentral (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2023

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---